Implant design helps fight ovarian cancer from the inside
A flexible, porous peritoneal implant can deliver live cell therapies repeatedly to ovarian cancer sites and sample peritoneal fluid for real‑time monitoring, sustaining function up to 70 days and improving tumor control versus conventional treatment in pre‑clinical studies.
A flexible, porous peritoneal implant designed for repeated local delivery of living cell therapies and real‑time monitoring of ovarian cancer remains functional for up to 70 days and shows superior tumor control compared with conventional treatments in pre‑clinical studies.
Localized, repeatable therapy delivery combined with real‑time tumor environment sampling could improve outcomes for ovarian cancer, which is frequently diagnosed late and lacks effective targeted treatments.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- Scientists discover why cancer drugs don’t work for everyone
- Epithelial ovarian cancer: prevention, diagnosis, and treatment
- Gynecologic Cancer InterGroup Consensus Recommendations on Clinical Research in Ovarian Cancer
- Why anti‑estrogen therapy fails in ovarian cancer, and how to make it work
- Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements